P-glycoprotein in acute myeloid leukaemia: Therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype

Leukemia and Lymphoma

Volumn 43, Issue 6, 2002, Pages 1221-1228

  Pallis, Monica ^a   Turzanski, Julie ^a   Higashi, Yutaro ^a   Russell, Nigel ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

AML; Apoptosis; Drug resistance; P glycoprotein

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; BRYOSTATIN; CERAMIDE; CYCLOSPORIN A; CYTARABINE; CYTOKINE; CYTOTOXIC AGENT; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GLYCOPROTEIN P; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IDARUBICIN; LIPID; MEVINOLIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN KINASE C INHIBITOR; SIMVASTATIN; STAUROSPORINE; TAMOXIFEN; VALSPODAR; VERAPAMIL; ANTINEOPLASTIC AGENT; CYCLOSPORIN; CYCLOSPORIN DERIVATIVE; ENZYME INHIBITOR; ORGANOARSENIC DERIVATIVE; OXIDE; PROTEIN KINASE C; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BLAST CELL; CANCER CHEMOTHERAPY; CELL PH; CHEMOSENSITIVITY; CLINICAL STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG UPTAKE; HUMAN; IN VITRO STUDY; LEUKEMIA REMISSION; MODULATION; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ACUTE DISEASE; ADULT; CELL CULTURE; CELL DIVISION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; MULTICENTER STUDY; MYELOID LEUKEMIA; PATHOLOGY; PH; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TRANSPORT AT THE CELLULAR LEVEL;

ACUTE DISEASE; ADULT; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BIOLOGICAL TRANSPORT; CELL DIVISION; CERAMIDES; CHILD; CYCLOSPORINE; CYCLOSPORINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMAN; HYDROGEN-ION CONCENTRATION; LEUKEMIA, MYELOID; LOVASTATIN; MULTICENTER STUDIES; NEOPLASM PROTEINS; OXIDES; P-GLYCOPROTEIN; PHENOTYPE; PROTEIN KINASE C; RANDOMIZED CONTROLLED TRIALS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; HUMANS;

EID: 0035992274     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190290026277     Document Type: Review

References (95)

1. "Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukaemia cells at diagnosis"
2. "P-glycoprotein expression in patients with acute leukemia-clinical relevance"
3. "Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia"
4. "Multidrug resistance gene expression in acute myeloid leukemia: Major prognosis significance for in vivo drug resistance to induction treatment"
5. "Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A southwest oncology group study"
6. "Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A southwest oncology group study"
7. "MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia"
8. "P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia"
9. "Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics"
10. "Drug resistance factors in acute myeloid leukemia: A comparative analysis"
11. "Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute group: A report from the Childrens Cancer Group"
12. "Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study"
13. "Comparison of 'sequential' versus 'standard' chemotherapy as reinduction treatment, with or without cyclosporine, in refractory/r-elapsed acute myeloid leukaemia (AML): Results of the UK Medical Research Council AML-R trial"
14. "Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients (pts) ≥60 years (CALGB 9720)"
15. "Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance"
16. "Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: Implications for liposome-encapsulated daunorubicin"
17. "Liposome-encapsulated daunorubicin for PGP-related multidrug resistance"
18. "Liposomal daunorubicin plus cytosine arabinoside for elderly patients with acute myeloid leukemia. The GIMEMA experience"
19. "Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia"
20. "Targeted AML therapy: New biologic paradigms and therapeutic opportunities"
21. "New agents for induction and postremission therapy of acute myeloid leukemia"
22. "FLAG (fludarabine + high-dose cytarabine + G-CSF): An effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias"
23. "Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia"
24. "Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia"
25. "A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo with excess of blasts in transformation"
26. "Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukaemia during therapy"
27. "FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: In vitro and in vivo effects"
28. "Effect of fludarabine and arabinosylcytosine on multidrug resistant cells"
29. "Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive P-glycoprotein-negative acute myeloblastic leukaemia"
30. "Comparative cellular pharmacology of daunorubicin and idarubicin in human multi-drug-resistant leukemia cells"
31. "A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives"
32. "P-glycoprotein expression in acute myeloid leukaemia cells at diagnosis: Its relationship to daunorubicin or idarubicin induction therapy and survival; Malignancy"
33. "IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: Experiences of a phase II trial"
34. "Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML"
35. "Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia"
36. "Cholesterol based antineoplastic strategies"
37. "Interaction of cytosine arabinoside and lovastatin in human leukemia cells"
38. "Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells"
39. "A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemia and normal bone marrow progenitors"
40. "Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach"
41. "Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin"
42. "Inhibition of protein kinase C-do we, can we, and should we?"
43. "Protein kinase C targeting in antineoplastic treatment strategies"
44. "The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors"
45. "Bryostatin 1, a unique biologic response modifier: Anti-leukemic activity in vitro"
46. "Tumor cell terminal differentiation requires cell cycle inhibition combined with growth factors"
47. "Equivalent death of P-glycoprotein expressing and nonexpressing cells induced by the protein kinase C inhibitor staurosporine"
48. "P-glycoprotein, multidrug resistance and protein kinase C"
49. "Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells"
50. "Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway"
51. "Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines"
52. "Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L)"
53. "Inhibited apoptosis and drug resistance in acute myeloid leukaemia"
54. "P-glycoprotein expression is associated with resistance to spontaneous in vitro apoptosis in AML"
55. "Bcl-x[L] is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression"
56. "Human MDR 1 protein over-expression delays the apoptotic cascade in Chinese hamster ovary fibroblasts"
57. "The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis"
58. "P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death"
59. "P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway"
60. "Daunorubicin-induced apoptosis-triggering of ceramide generation through sphingomyelin hydrolysis"
61. "Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating cell death signals"
62. "MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine"
63. "Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein"
64. "Restoration of TNF-α-induced ceramide generation and apoptosis in resistant leukemia KG1a cells by the p-glycoprotein blocker PSC833"
65. "Mechanisms of hepatic transport of cyclosporin A: An explanation for its cholestatic action?"
66. "SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein"
67. "Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia"
68. "Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells"
69. "Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase"
70. "Retroviral transfection of Madin-Darby canine kidney cells with human MDR1 results in a major increase in globotriaosylceramide and 10(5)- to Role of p-glycoprotein in glycolipid synthesis"
71. "P-glycoprotein expression in the golgi apparatus of multidrug-resistant cells"
72. "Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles"
73. "Increased cytosolic pH in multidrug-resistant human lung tumor cells: Effect of verapamil"
74. "Investigation of the relationship between altered intracellular pH and multidrug resistance in mammalian cells"
75. "Activity of the multidrug transporter results in alklinazation of the cytosol: Measurement of cytosolic pH by microinjection of a pH-sensitive dye"
76. "Changes in intra- or extracellular pH do not mediate P-glycoprotein-dependent multidrug resistance"
77. "pH regulation in sensitive and multidrug resistant Ehrlich ascites tumor cells"
78. "Are altered pHi and membrane potential in hu MDR 1 transfectants sufficient to cause MDR protein-mediated multidrug resistance?"
79. "In situ biochemical demonstration that P-glycoprotein is a drug efflux pump with broad specificity"
80. "Role of intracellular pH in proliferation, transformation, and apoptosis"
81. "Regulation of volume-activated chloride channels by P-glycoprotein: Phosphorylation has the final say!"
82. "Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes"
83. "Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes"
84. "P-glycoprotein (encoded by multidrug resistance genes) is not required for interleukin-2 secretion in mice and humans"
85. "Multidrug-resistant cells with high proliferative capacity determine response to therapy in acute myeloid-leukemia"
86. "In vitro growth in acute myeloblastic leukaemia: Relationship with other clinico-biological characteristics of the disease"
87. "Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice"
88. "Modulation of multidrug resistance in de novo adult acute myeloid laukaemia: Variable efficacy of reverting agents in vitro"
89. "Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR - /efflux + and MDR1 + /efflux - cases"
90. "P-glycoprotein (pgp) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells"
91. "Comparison of p-glycoprotein expression with in vitro drug-sensitivity in fresh blast cells from acute myeloid-leukemia patients"
92. "Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?"
93. "MDR1 gene expression and drug resistance of AML cells"
94. "MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia"
95. "Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells"